Roche Holding AG (RHHBF) Stock
Roche Holding AG

Company profile
Roche Holding reported revenue of 63.36 billion CHF for fiscal year 2025, up 1.5% from fiscal year 2024, and net income of 12.88 billion CHF. That is a net profit margin of 20.3% for fiscal year 2025. Its largest business segment, Pharmaceuticals - Roche Pharmaceuticals, brought in 70% of segment revenue in fiscal year 2025; United States was the largest region with 48%. Our analysis of its filings shows revenue growing from 60.44 billion CHF in fiscal year 2023 to 63.36 billion CHF in fiscal year 2025, 2.4% a year on average.
What stands out
- It spent 13.35 billion CHF on research and development in fiscal year 2025, 21.1% of its revenue.
- It was founded in 1896.
Figures from company filings; latest fiscal year ended December 31, 2025.
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. The company was founded in 1896 and is based in Basel, Switzerland.
Largest shareholders
- Sjunde Ap Fonden (Investment Management)0.16%
- Dws Ch AG0.11%
- Baloise Asset Management AG0.11%
- Goldman Sachs Asset Management International0.10%
- Basellandschaftliche Kantonalbank (Investment Management)0.09%
Share of the company, as of September 25, 2026
Leadership
- Thomas Schinecker — Group Chief Executive Officer, 50
- Severin Schwan Ph.D. — Executive Chairman, 58
- Alan Hippe — Chief Financial Officer, 58
- Pascale Schmidt — Chief Compliance Officer, 52
- Maria Cristina A. Wilbur — Chief People Officer, 58
In the news
- AZENTA ANNOUNCES LEADERSHIP TRANSITION
- Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets
- Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development
- Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX?
How much revenue does Roche Holding make?
Roche Holding reported 63.36 billion CHF in revenue for fiscal year 2025, up 1.5% from 62.40 billion CHF in fiscal year 2024.
What is Roche Holding's largest business segment?
Pharmaceuticals - Roche Pharmaceuticals, with 48.07 billion CHF or 70% of segment revenue in fiscal year 2025. Next: Diagnostics (20%) and Pharmaceuticals - Chugai (10%).
Where does Roche Holding make most of its revenue?
United States: 48% of revenue by region in fiscal year 2025, followed by Rest of Europe (17%).
What companies are similar to Roche Holding?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Novartis AG (NVS), AstraZeneca PLC (AZN), Inventage Lab, Inc. (389470.KQ), JW Holdings Corporation (096760.KS).
Company Information
Data as of .
How to cite: DataPorium, “Roche Holding AG (RHHBF)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/RHHBF